0001209191-19-024958.txt : 20190417 0001209191-19-024958.hdr.sgml : 20190417 20190417160305 ACCESSION NUMBER: 0001209191-19-024958 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190415 FILED AS OF DATE: 20190417 DATE AS OF CHANGE: 20190417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lemkey John G CENTRAL INDEX KEY: 0001495904 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38318 FILM NUMBER: 19753088 MAIL ADDRESS: STREET 1: 4401 EASTGATE MALL CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Odonate Therapeutics, Inc. CENTRAL INDEX KEY: 0001717452 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822493065 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 510 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-200-3830 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE STREET 2: SUITE 510 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Odonate Therapeutics, Inc DATE OF NAME CHANGE: 20171207 FORMER COMPANY: FORMER CONFORMED NAME: Odonate Therapeutics, LLC DATE OF NAME CHANGE: 20170919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-04-15 0 0001717452 Odonate Therapeutics, Inc. ODT 0001495904 Lemkey John G C/O ODONATE THERAPEUTICS, INC. 4747 EXECUTIVE DRIVE, SUITE 510 SAN DIEGO CA 92121 0 1 0 0 Chief Operating Officer Common Stock 2019-04-15 4 A 0 53 21.24 A 1431 D Common Stock 13086038 I By LP Employee Stock Option (Right to Buy) 24.99 2019-04-15 4 A 0 53 0.00 A 2029-04-15 Common Stock 53 53 D These shares were acquired on 04/15/2019 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. John Lemkey is the Chief Operating Officer of Odonate Therapeutics, Inc., as well as Chief Operating Officer of TCM. Mr. Lemkey has a pecuniary interest in a portion of the shares beneficially held by TCP. The stock options vest with respect to 25% of the underlying shares on 04/15/2020, with the remaining shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. /s/ John Lemkey 2019-04-17